Table 2.

Comparison of patients with and without an increase in tricuspid regurgitation (TR) after cardiac device implantation — procedure-related variables.

Variable	With an increase in TR (n = 17)	Without an increase in TR (n = 93)	P
Cardiac device type
DDD	71%; 12/17	51%; 47/93	0.19
VVI	12%; 2/17	28%; 26/93	0.23
ICD	18%; 3/17	19%; 18/93	1.00
CRT	0%; 0/17	2.2%; 2/93	1.00
Number of leads
1	29%; 5/17	42%; 39/93	0.42
2	71%; 12/17	56%; 52/93	0.30
3	0%; 0/17	2.2%; 2/93	1.00
Type/localization of lead
Atrial	71%; 12/17	58%; 54/93	0.42
Ventricular for stimulation	82%; 14/17	79%; 73/93	1.00
Ventricular for defibrillation	18%; 3/17	22%; 20/93	1.00
Manufacturer
Biotronik	65%; 11/17	51%; 47/93	0.50
Medtronic	35%; 6/17	32%; 30/93	0.80
St. Jude Medical	0%; 0/17	17%; 16/93	0.13
Operator			0.051
Operator no. 1	0%; 0/13*	100%; 13/13*
Operator no. 2	27%; 3/11*	73%; 8/11*
Operator no. 3	11%; 3/27*	89%; 24/27*
Operator no. 4	50%; 3/6*	50%; 3/6*
Operator no. 5	15%; 8/53*	85%; 45/53*

^*Refers to the number of procedures performed by the given operator;

DDD — dual-chamber pacemaker; CRT — cardiac resynchronization therapy; ICD — implantable cardioverter defibrillator; VVI — ventricular single-chamber pacemaker